| 标题： | 基因检测指导呼吸系统疾病多重用药专家共识 |
| title： | Expert consensus on multiple drug use for respiratory system diseases guided by genetic testing |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医生、药师、护士、检验技师 |
| Guide users： | Doctors, pharmacists, nurses, laboratory technicians |
| 证据分级方法： | 2011版牛津循证医学中心分级系统（OCEBM）作为评价工具 |
| Evidence grading method： | OCEBM |
| 制定单位： | 上海交通大学医学院附属新华医院 |
| Formulating unit： | Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine |
| 注册时间： | 2023-10-30 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN820 |
| Registration number： | |
| 指南制订的目的： | 呼吸系统慢性病患者多重用药非常普遍，而有些药物受相同的药物代谢酶或转运蛋白影响，从而影响疗效或产生不良反应。通过检测基因来合理调整用药也是非常必要的手段。中华医学会临床药学分会组织相关专家，针对呼吸系统慢性病多重用药的患者，欲利用国外用药风险评估工具，结合相关循证结果，制定了我国《基因检测指导呼吸系统疾病多重用药专家共识》，进一步推广应用于呼吸系统临床疾病治疗实践，为个别机构制定临床方案提供信息，以减少我国多重用药的不良临床结局。 |
| Purpose of the guideline： | Multiple medication is very common in patients with chronic respiratory diseases, and some drugs are affected by the drug metabolism enzymes or transporters, thereby affecting the efficacy or producing adverse reactions. Reasonably adjusting medication through gene testing is also a necessary means. The Clinical Pharmacy Branch of the Chinese Medical Association has organized relevant experts to use foreign drug risk assessment tools and relevant evidence-based results to develop the "Expert Consensus on Gene Testing Guidance for Multiple Drug Use in Respiratory System Diseases" for patients with chronic respiratory diseases who use multiple drugs. The consensus will be further promoted and applied to the clinical treatment practice of respiratory diseases, providing information for individual institutions to develop clinical plans and reduce the adverse clinical outcomes of multiple drug use in China. |
